monica.martinez.fernandez@usc.es
Dra. Mónica Martínez-Fernández is author of most of 30 papers in high-impact oncology journals (JCI, Clinical Cancer Research, Cancer Research, Oncogene, etc). She is responsible of the research line “Translational Molecular Oncology” focused on understanding the molecular alterations leading to tumor development and evolution, trying to translate the basic research results into the clinic. She has an Investigator contract funded by the Spanish Association Against Cancer (AECC), leading a project aimed to understand the oncogenic role of retrotransposons highly mutagenic in certain tumours.
Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet
Martinez VG, Munera-Maravilla E, Bernardini A, Rubio C, Suarez-Cabrera C, Segovia C, Lodewijk I, Dueñas M, Martínez-Fernández M and Paramio JM
Front. Genet. 10:1125.doi: 10.3389/fgene.2019.01125
*
, Edurne San José-Enériz*
, Ester Munera-Maravilla*
, Mónica Martínez-Fernández, Leire Garate, Estíbaliz Miranda, Amaia Vilas-Zornoza, Iris Lodewijk, Carolina Rubio, Carmen Segrelles, Luis Vitores Valcárcel, Obdulia Rabal, Noelia Casares, Alejandra Bernardini, Cristian Suarez-Cabrera, Fernando F. López-Calderón, Puri Fortes, José A. Casado, Marta Dueñas, Felipe Villacampa, Juan José Lasarte, Félix Guerrero-Ramos, Guillermo de Velasco, Julen Oyarzabal, Daniel Castellano, Xabier Agirre, Felipe Prósper & Jesús M. Paramio. Equal contributions Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status
Marta Dueñas, Andrés Pérez-Figueroa, Carla Oliveira, Cristian Suárez-Cabrera, Abel Sousa, Patricia Oliveira, Felipe Villacampa, Jesús M. Paramio & Mónica Martínez-Fernández
Scientific Reports volume 9, Article number: 10362 (2019)
doi: 10.1038/s41598-019-46652-4
CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status.
Rubio *
, Martínez-Fernández*
, Segovia, Lodewijk, Suarez-Cabrera, Segrelles, López-Calderón, Munera-Maravilla, Santos, Bernardini, García-Escudero, Lorz, Gómez-Rodriguez, de Velasco, Otero, Villacampa, Guerrero-Ramos, Ruiz, de la Rosa, Domínguez-Rodríguez, Real, Malats, Castellano, Dueñas, Paramio. (*
=equal contribution)
Clin Cancer Res. 2019 Jan 1;25(1):390-402.
doi: 10.1158/1078-0432.CCR-18-0685. Epub 2018 Sep 21.
BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer
Martínez VG, Rubio C, Martínez-Fernández M et al,
Clin Cancer Res. 2017 Dec 1;23(23):7388-7399.
doi: 10.1158/1078-0432.CCR-17-1004. Epub 2017 Sep 19.
Epigenetic mutations and cancer therapy Effectiven(EZH2)
Cristina Segovia, Jesús M. Paramio, Mónica Martínez-Fernández
Submitted Apr 28, 2017.
Accepted for publication May 08, 2017.
Translational Cancer Research
doi: 10.21037/tcr.2017.05.27
Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.
Segovia C*
, Martínez-Fernández M*
, Dueñas M*
, Rubio C, López-Calderón FF et al. (*
=equal contribution)
2017 Oncotarget. 8:10531-10542.
RNA Detection in Urine: From RNA Extraction to Good Normalizer Molecules.
Martínez Fernández, M.; Paramio, JM.; Dueñas, M.
2016 The Journal of Molecular Diagnostics: 18-1, pp.15-37.
Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer.
Mónica Martínez-Fernández, Andrew Feber, et al.
2015. Clinical Epigenetics. 7, pp.109.
A Polycomb-mir200 loop regulates clinical outcome in bladder cancer
Mónica Martínez-Fernández, Marta Dueñas, Andrew Feber, et al.
2015 Oncotarget 6-39, pp.42258-42333.
NOTCH pathway inactivation promotes bladder cancer progression. The Journal of Clinical Investigation.
Antonio Maraver, Pablo J. Fernandez-Marcos,...Mónica Martínez-Fernández,.. et al.
2015 JCI 125-2, pp.824-854.
*
, Mónica Martínez-Fernández*
, Marta Dueñas, et al. (*
=equal contribution)